


**Amendments to the claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:


1. (ORIGINAL) A compound represented by the following Formula (I):



(I)

wherein:


R, R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are each independently selected from hydrogen, C<sub>1-6</sub>alkyl, -(CH<sub>2</sub>)<sub>p</sub>OR<sup>4</sup>, -C(O)OR<sup>4</sup>, formyl, nitro, cyano, halogen, aryl, substituted aryl, substituted alkyl, -S(O)<sub>n</sub>R<sup>4</sup>, cycloalkyl, -NR<sup>5</sup>R<sup>6</sup>, protected -OH, -CONR<sup>5</sup>R<sup>6</sup>, phosphonic acid, sulfonic acid, phosphinic acid, -SO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, a heterocyclic methylene substituent as represented by Formula (III),



(III),

and

a substituent as represented by Formula (VII),



where,

p is 0-6,

n is 0-2,

W and Z are each independently selected from C, O, S and NR<sup>16</sup>, where R<sup>16</sup> is selected from: hydrogen, alkyl, cycloalkyl, C<sub>1</sub>-C<sub>12</sub>aryl, substituted alkyl, substituted cycloalkyl and substituted C<sub>1</sub>-C<sub>12</sub>aryl,

V and X are each independently selected from O, S and NR<sup>16</sup>, where R<sup>16</sup> is selected from: hydrogen, alkyl, cycloalkyl, C<sub>1</sub>-C<sub>12</sub>aryl, substituted alkyl, substituted cycloalkyl and substituted C<sub>1</sub>-C<sub>12</sub>aryl,

R<sup>4</sup> is selected from: hydrogen, alkyl, cycloalkyl, C<sub>1</sub>-C<sub>12</sub>aryl, substituted alkyl, substituted cycloalkyl and substituted C<sub>1</sub>-C<sub>12</sub>aryl,

R<sup>5</sup> and R<sup>6</sup> are each independently selected from hydrogen, alkyl, substituted alkyl, C<sub>3</sub>-cycloalkyl, and aryl,

or R<sup>5</sup> and R<sup>6</sup> taken together with the nitrogen to which they are attached represent a 5 to 6 member saturated ring containing up to one other heteroatom selected from oxygen and nitrogen,

T is absent or selected from O, S and NR<sup>16</sup>, where R<sup>16</sup> is selected from: hydrogen, alkyl, cycloalkyl, C<sub>1</sub>-C<sub>12</sub>aryl, substituted alkyl, substituted cycloalkyl and substituted C<sub>1</sub>-C<sub>12</sub>aryl,

P is selected from OR<sup>4</sup>, SR<sup>4</sup>, NR<sup>5</sup>R<sup>6</sup>, and R<sup>4</sup>, where R<sup>4</sup> is selected from: hydrogen, alkyl, cycloalkyl, C<sub>1</sub>-C<sub>12</sub>aryl, substituted alkyl, substituted cycloalkyl and substituted C<sub>1</sub>-C<sub>12</sub>aryl,

R<sup>25</sup> is selected from: hydrogen, alkyl, cycloalkyl, C<sub>1</sub>-C<sub>12</sub>aryl, substituted alkyl, substituted cycloalkyl and substituted C<sub>1</sub>-C<sub>12</sub>aryl, and

R<sup>30</sup> is selected from: hydrogen, alkyl, cycloalkyl, C<sub>1</sub>-C<sub>12</sub>aryl, substituted alkyl, substituted cycloalkyl and substituted C<sub>1</sub>-C<sub>12</sub>aryl;

$R^{15}$  is selected from the group consisting of alkyl,  $C_1$ - $C_{12}$ aryl, hydroxy, alkoxy, substituted alkyl, substituted  $C_1$ - $C_{12}$ aryl and halogen;

m is 0-6; and

Y is a cyclic or polycyclic, unsaturated or saturated, non-aromatic ring containing from 3 to 16 carbon atoms and optionally substituted with one or more substituents selected from the group consisting of: alkyl, substituted alkyl, aryl, substituted cycloalkyl, substituted aryl, aryloxy, oxo, hydroxy, alkoxy, cycloalkyl, acyloxy, amino, N-acylamino, nitro, cyano, halogen, - $C(O)OR^4$ , - $C(O)NR^{10}R^{11}$ , - $S(O)_2NR^{10}R^{11}$ , - $S(O)_nR^4$  and protected -OH, where n is 0-2,

$R^4$  is hydrogen, alkyl, cycloalkyl,  $C_1$ - $C_{12}$ aryl, substituted alkyl, substituted cycloalkyl and substituted  $C_1$ - $C_{12}$ aryl, and


$R^{10}$  and  $R^{11}$  are independently hydrogen, cycloalkyl,  $C_1$ - $C_{12}$ aryl, substituted cycloalkyl, substituted  $C_1$ - $C_{12}$ aryl, alkyl or alkyl substituted with one or more substituents selected from the group consisting of: alkoxy, acyloxy, aryloxy, amino, N-acylamino, oxo, hydroxy, - $C(O)OR^4$ , - $S(O)_nR^4$ , - $C(O)NR^4R^4$ , - $S(O)_2NR^4R^4$ , nitro, cyano, cycloalkyl, substituted cycloalkyl, halogen, aryl, substituted aryl and protected -OH, or  $R^{10}$  and  $R^{11}$  taken together with the nitrogen to which they are attached represent a 5 to 6 member saturated ring containing up to one other heteroatom selected from oxygen and nitrogen,

where  $R^4$  is as described above and n is 0-2;

and pharmaceutically acceptable salts, hydrates, solvates and esters thereof;


provided that at least one of R,  $R^1$ ,  $R^2$  and  $R^3$  is a substituted aryl group or a heterocyclic methylene substituent as represented in Formula (III) or a substituent as represented in Formula (VII).

2. (ORIGINAL) A compound of claim 1 represented by the following Formula (II):




wherein:

R, R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are each independently selected from hydrogen, C<sub>1-6</sub>alkyl, -(CH<sub>2</sub>)<sub>p</sub>OR<sup>4</sup>, -C(O)OR<sup>4</sup>, formyl, nitro, cyano, halogen, aryl, substituted aryl, substituted alkyl, -S(O)<sub>n</sub>R<sup>4</sup>, cycloalkyl, -NR<sup>5</sup>R<sup>6</sup>, protected -OH, -CONR<sup>5</sup>R<sup>6</sup>, phosphonic acid, sulfonic acid, phosphinic acid, -SO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, a heterocyclic methylene substituent as represented by Formula (III),



and

a substituent as represented by Formula (VII),



where,

p is 0-6,

n is 0-2,

W and Z are each independently selected from C, O, S and  $\text{NR}^{16}$ , where  $\text{R}^{16}$  is selected from: hydrogen, alkyl, cycloalkyl,  $\text{C}_1\text{-C}_{12}\text{aryl}$ , substituted alkyl, substituted cycloalkyl and substituted  $\text{C}_1\text{-C}_{12}\text{aryl}$ ,

V and X are each independently selected from O, S and  $\text{NR}^{16}$ , where  $\text{R}^{16}$  is selected from: hydrogen, alkyl, cycloalkyl,  $\text{C}_1\text{-C}_{12}\text{aryl}$ , substituted alkyl, substituted cycloalkyl and substituted  $\text{C}_1\text{-C}_{12}\text{aryl}$ ,

$\text{R}^4$  is selected from: hydrogen, alkyl, cycloalkyl,  $\text{C}_1\text{-C}_{12}\text{aryl}$ , substituted alkyl, substituted cycloalkyl and substituted  $\text{C}_1\text{-C}_{12}\text{aryl}$ ,

$\text{R}^5$  and  $\text{R}^6$  are each independently selected from hydrogen, alkyl, substituted alkyl,  $\text{C}_3\text{-cycloalkyl}$ , and aryl,

or  $\text{R}^5$  and  $\text{R}^6$  taken together with the nitrogen to which they are attached represent a 5 to 6 member saturated ring containing up to one other heteroatom selected from oxygen and nitrogen,

T is absent or selected from O, S and  $\text{NR}^{16}$ , where  $\text{R}^{16}$  is selected from: hydrogen, alkyl, cycloalkyl,  $\text{C}_1\text{-C}_{12}\text{aryl}$ , substituted alkyl, substituted cycloalkyl and substituted  $\text{C}_1\text{-C}_{12}\text{aryl}$ ,

P is selected from  $\text{OR}^4$ ,  $\text{SR}^4$ ,  $\text{NR}^5\text{R}^6$ , and  $\text{R}^4$ , where  $\text{R}^4$  is selected from: hydrogen, alkyl, cycloalkyl,  $\text{C}_1\text{-C}_{12}\text{aryl}$ , substituted alkyl, substituted cycloalkyl and substituted  $\text{C}_1\text{-C}_{12}\text{aryl}$ ,

$\text{R}^{25}$  is selected from: hydrogen, alkyl, cycloalkyl,  $\text{C}_1\text{-C}_{12}\text{aryl}$ , substituted alkyl, substituted cycloalkyl and substituted  $\text{C}_1\text{-C}_{12}\text{aryl}$ , and

$\text{R}^{30}$  is selected from: hydrogen, alkyl, cycloalkyl,  $\text{C}_1\text{-C}_{12}\text{aryl}$ , substituted alkyl, substituted cycloalkyl and substituted  $\text{C}_1\text{-C}_{12}\text{aryl}$ ;

$\text{R}^{15}$  is selected from the group consisting of alkyl,  $\text{C}_1\text{-C}_{12}\text{aryl}$ , hydroxy, alkoxy, substituted alkyl, substituted  $\text{C}_1\text{-C}_{12}\text{aryl}$  and halogen;

m is 0-6; and

Y is a cyclic or polycyclic, unsaturated or saturated, non-aromatic ring containing from 5 to 14 carbon atoms and optionally substituted with one or more substituents selected from the group

consisting of: alkyl, substituted alkyl, aryl, substituted cycloalkyl, substituted aryl, aryloxy, oxo, hydroxy, alkoxy, cycloalkyl, acyloxy, amino, N-acylamino, nitro, cyano, halogen, -C(O)OR<sup>4</sup>, -C(O)NR<sup>10</sup>R<sup>11</sup>, -S(O)<sub>2</sub>NR<sup>10</sup>R<sup>11</sup>, -S(O)<sub>n</sub>R<sup>4</sup> and protected -OH,

where n is 0-2,

R<sup>4</sup> is hydrogen, alkyl, cycloalkyl, C<sub>1</sub>-C<sub>12</sub>aryl, substituted alkyl, substituted cycloalkyl and substituted C<sub>1</sub>-C<sub>12</sub>aryl, and

R<sup>10</sup> and R<sup>11</sup> are independently hydrogen, cycloalkyl, C<sub>1</sub>-C<sub>12</sub>aryl, substituted cycloalkyl, substituted C<sub>1</sub>-C<sub>12</sub>aryl, alkyl or alkyl substituted with one or more substituents selected from the group consisting of: alkoxy, acyloxy, aryloxy, amino, N-acylamino, oxo, hydroxy, -C(O)OR<sup>4</sup>, -S(O)<sub>n</sub>R<sup>4</sup>, -C(O)NR<sup>4</sup>R<sup>4</sup>, -S(O)<sub>2</sub>NR<sup>4</sup>R<sup>4</sup>, nitro, cyano, cycloalkyl, substituted cycloalkyl, halogen, aryl, substituted aryl and protected -OH, or R<sup>10</sup> and R<sup>11</sup> taken together with the nitrogen to which they are attached represent a 5 to 6 member saturated ring containing up to one other heteroatom selected from oxygen and nitrogen,

where R<sup>4</sup> is as described above and n is 0-2;

and pharmaceutically acceptable salts, hydrates, solvates and esters thereof;

provided that at least one of R, R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> is a substituted aryl group or a heterocyclic methylene substituent as represented in Formula (III) or a substituent as represented in Formula (VII).

3. (ORIGINAL) A compound represented by Formula (II), as defined in claim 2, wherein:

R is a substituted aryl; and R<sup>1</sup> is hydrogen;

R is hydrogen; and R<sup>1</sup> is a substituted aryl;

R is a hydrogen; and R<sup>1</sup> is a substituent as represented in Formula (III); or

R is a hydrogen; and R<sup>1</sup> is a substituent as represented in Formula (VII);

and in each of the above cases:

$R^2$  and  $R^3$  are each independently selected from hydrogen,  $C_{1-6}$ alkyl,  $C_{1-6}$ alkoxy, nitro, cyano, halogen, aryl, substituted aryl, substituted alkyl, cycloalkyl, phosphonic acid, phosphinic acid and sulfonic acid;

$R^{15}$  is selected from the group consisting of alkyl, substituted alkyl,  $C_1$ - $C_{12}$ aryl, alkoxy and halogen;

m is 0-4; and

Y is selected from,

cyclohexyl, cyclopentyl and cycloheptyl, where the cyclohexyl, cyclopentyl and cycloheptyl are optionally substituted with from one to three substituents selected from the group consisting of: alkyl, substituted alkyl,  $C_1$ - $C_{12}$ aryl, substituted  $C_1$ - $C_{12}$ aryl, alkoxy and halogen;

and pharmaceutically acceptable salts, hydrates, solvates and esters thereof.

4. (ORIGINAL) A compound represented by Formula (II), as defined in claim 2, wherein:

R is a substituted  $C_1$ - $C_{12}$ aryl; and  $R^1$  is hydrogen;

R is a hydrogen; and  $R^1$  is a substituent as represented in Formula (III); or

R is a hydrogen; and  $R^1$  is a substituent as represented in Formula (VII);

and in each of the above cases:

$R^2$  and  $R^3$  are each independently selected from hydrogen,  $C_{1-6}$ alkyl,  $C_{1-6}$ alkoxy, nitro, cyano, halogen, substituted alkyl and cycloalkyl;

$R^{15}$  is selected from the group consisting of alkyl, substituted alkyl,  $C_1$ - $C_{12}$ aryl, alkoxy and halogen;

m is 0-2; and

Y is selected from,

cyclohexyl, cyclopentyl and cycloheptyl, where the cyclohexyl, cyclopentyl and cycloheptyl are optionally substituted with from one to three substituents selected from the group consisting of: alkyl, substituted alkyl, C<sub>1</sub>-C<sub>12</sub>aryl, substituted C<sub>1</sub>-C<sub>12</sub>aryl, alkoxy and halogen;

and additionally, when R is a hydrogen; and R<sup>1</sup> is a substituent as represented in Formula (VII);

R<sup>25</sup> and R<sup>30</sup> are each selected from: hydrogen, C<sub>1</sub>-<sub>6</sub>alkyl, C<sub>1</sub>-<sub>6</sub>alkoxy, substituted C<sub>1</sub>-<sub>6</sub>alkyl and cycloalkyl;

and additionally, when R is a hydrogen; and R<sup>1</sup> is a substituent as represented in Formula (VII); and

when R is a hydrogen; and R<sup>1</sup> is a substituent as represented in Formula (III);

R<sup>4</sup> is selected from: hydrogen, C<sub>1</sub>-<sub>6</sub>alkyl, C<sub>1</sub>-<sub>6</sub>alkoxy, substituted C<sub>1</sub>-<sub>6</sub>alkyl and cycloalkyl; and pharmaceutically acceptable salts, hydrates, solvates and esters thereof.

5. (ORIGINAL) A compound represented by Formula (II), as defined in claim 2, wherein:

R is a substituted phenyl ring and R<sup>1</sup> is hydrogen; or

R is a hydrogen; and R<sup>1</sup> is a substituent as represented in Formula (III);

and in either of the above cases:

R<sup>2</sup> and R<sup>3</sup> are each independently selected from hydrogen, C<sub>1</sub>-<sub>6</sub>alkyl, substituted alkyl and halogen;

R<sup>15</sup> is selected from the group consisting of C<sub>1</sub>-<sub>4</sub>alkyl, C<sub>1</sub>-<sub>4</sub>alkoxy, C<sub>1</sub>-C<sub>12</sub>aryl and halogen;

m is 0; and

Y is selected from,

cyclohexyl, cyclopentyl and cycloheptyl, where cyclohexyl, cyclopentyl and cycloheptyl are optionally substituted with from one to three substituents selected from the group consisting of: alkyl, substituted alkyl, C<sub>1</sub>-C<sub>12</sub>aryl, substituted C<sub>1</sub>-C<sub>12</sub>aryl, alkoxy and halogen;



and additionally, when R is a hydrogen; and R<sup>1</sup> is a substituent as represented in Formula (III);

R<sup>4</sup> is selected from: hydrogen, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, substituted C<sub>1-6</sub>alkyl and cycloalkyl;  
and pharmaceutically acceptable salts, hydrates, solvates and esters thereof.

6. (ORIGINAL) A compound of claim 1 selected from:

3'-(1-Cyclohexyl-5-hydroxy-3-methyl-1H-pyrazol-4-ylazo)-2'-hydroxy-biphenyl-3-carboxylic acid;

3'-[1-(4-tert-Butyl-cyclohexyl)-5-hydroxy-3-methyl-1H-pyrazol-4-ylazo]-2'-hydroxy-biphenyl-3-carboxylic acid;

3'-[1-(3,4-Dimethyl-cyclohexyl)-5-hydroxy-3-methyl-1H-pyrazol-4-ylazo]-2'-hydroxy-biphenyl-3-carboxylic acid;

3'-[1-(3,4-Dichloro-cyclohexyl)-5-hydroxy-3-methyl-1H-pyrazol-4-ylazo]-2'-hydroxy-biphenyl-3-carboxylic acid;

5-[4-(1-Cyclohexyl-5-hydroxy-3-methyl-1H-pyrazol-4-ylazo)-3-hydroxy-benzylidene]-thiazolidine-2,4-dione;

5-{4-[1-(4-tert-Butyl-cyclohexyl)-5-hydroxy-3-methyl-1H-pyrazol-4-ylazo]-3-hydroxy-benzylidene}-thiazolidine-2,4-dione;

5-{4-[1-(3,4-Dimethyl-cyclohexyl)-5-hydroxy-3-methyl-1H-pyrazol-4-ylazo]-3-hydroxy-benzylidene}-thiazolidine-2,4-dione;

5-{4-[1-(3,4-Dichloro-cyclohexyl)-5-hydroxy-3-methyl-1H-pyrazol-4-ylazo]-3-hydroxy-benzylidene}-thiazolidine-2,4-dione;

(E)-3-{4-[1-(4-tert-butylcyclohexyl)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-4-ylazo]-3-hydroxyphenyl}-2-methylacrylic acid;

(E)-3-(4-{N'-3-Ethylcyclopentyl}-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]-hydrazino}-3-hydroxyphenyl)-2-methylacrylic acid; and

(E)-3-[4-(N'-(1-[3-(1,1-Dimethylpropyl)-cyclopentyl]-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene)-hydrazino)-3-hydroxyphenyl]-2-methylacrylic acid;  
and pharmaceutically acceptable salts, hydrates, solvates and esters thereof.

7. (ORIGINAL) A compound of claim 1 which is

3'-[N'-(1-cyclohexyl-3-methyl-5-oxo-1,5-dihydro-pyrazol-4-ylidene)-hydrazino]-2'-hydroxy-biphenyl-3-carboxylic acid;  
or pharmaceutically acceptable salt, hydrate, solvate and ester thereof.

8. (ORIGINAL) A method of treating of thrombocytopenia in a mammal, including a human, in need thereof which comprises administering to such mammal a therapeutically effective amount of a compound of Formula (I), as described in claim 1.

9. (ORIGINAL) A method as claimed in claim 8, wherein the mammal is a human.

10. (ORIGINAL) The method of claim 9 wherein the compound is selected from the compounds listed in claim 6.


Claims 11 to 13 (CANCELLED).

14. (ORIGINAL) A pharmaceutical composition for use in enhancing platelet production which comprises a compound of claim 1 and a pharmaceutically acceptable carrier.


Claims 15 to 18 (CANCELLED).

19. (ORIGINAL) A process for preparing a pharmaceutical composition containing a pharmaceutically acceptable carrier or diluent and an effective amount of a compound of the Formula (I) as described in claim 1 and pharmaceutically acceptable salts, hydrates, solvates and esters thereof which process comprises bringing the compound of the Formula (I) into association with the pharmaceutically acceptable carrier or diluent.

20. (ORIGINAL) A process for preparing a compound of Formula (II) by reaction of a compound of Formula (XX)



or a protected form thereof with a compound of Formula (XXI) or tautomeric equivalent (XXII)



wherein

$R$  is a substituted aryl; and  $R^1$  is hydrogen;

$R$  is hydrogen; and  $R^1$  is a substituted aryl;

$R$  is a hydrogen; and  $R^1$  is a substituent as represented in Formula (III); or

$R$  is a hydrogen; and  $R^1$  is a substituent as represented in Formula (VII);

and in each of the above cases:

$R^2$  and  $R^3$  are each independently selected from hydrogen,  $C_{1-6}$ alkyl,  $C_{1-6}$ alkoxy, nitro, cyano, halogen, aryl, substituted aryl, substituted alkyl, cycloalkyl, phosphonic acid, phosphinic acid and sulfonic acid;

$R^{15}$  is selected from the group consisting of alkyl, substituted alkyl,  $C_1$ - $C_{12}$ aryl, alkoxy and halogen;

$m$  is 0-4; and

$Y$  is selected from,

cyclohexyl, cyclopentyl and cycloheptyl, where the cyclohexyl, cyclopentyl and cycloheptyl are optionally substituted with from one to three substituents selected from the group consisting of: alkyl, substituted alkyl, C<sub>1</sub>-C<sub>12</sub>aryl, substituted C<sub>1</sub>-C<sub>12</sub>aryl, alkoxy and halogen;

followed if necessary or desired by salt formation.

Claims 21 to 37 (CANCELLED).

38. (ORIGINAL) A method of claim 8 wherein said thrombocytopenia is due to myelosuppression caused by chemotherapy or radiation therapy.
39. (ORIGINAL) A method of claim 8 wherein said thrombocytopenia is due to an organ transplant.
40. (ORIGINAL) A method of claim 8 wherein said thrombocytopenia is due to bone marrow, stem cell, or liver transplant.
41. (ORIGINAL) A method of claim 8 wherein said thrombocytopenia is due to idiopathic thrombocytopenia purpura (ITP).
42. (ORIGINAL) A method of claim 8 wherein said thrombocytopenia is due to myelodysplastic syndromes (MDS), aplastic anemia or leukemia.
43. (ORIGINAL) A method of claim 8 wherein said thrombocytopenia is due to viral, fungal, microbial or parasitic infection.

44. (ORIGINAL) A method of claim 8 wherein said thrombocytopenia is due to liver dysfunction.
45. (ORIGINAL) A method of claim 8 wherein said thrombocytopenia is due to surgical procedures.
46. (ORIGINAL) A method of claim 8 wherein said thrombocytopenia is due to treatment with antiviral or antibiotic agents.

Claims 47 and 48 (CANCELLED).

49. (ORIGINAL) A compound of Claim 6 selected from:  
3'-[N'-(1-cyclohexyl-3-methyl-5-oxo-1,5-dihydro-pyrazol-4-ylidene)-hydrazino]-2'-hydroxy-biphenyl-3-carboxylic acid;  
or pharmaceutically acceptable salt, hydrate, solvate and ester thereof.
50. (ORIGINAL) An intermediate used in the preparation of compounds of Claim 1 selected from:  
2-Cyclohexyl-5-methyl-2,4-dihydro-pyrazol-3-one;  
2-(4-tert-Butyl-cyclohexyl)-5-methyl-2,4-dihydro-pyrazol-3-one;  
5-(3-Hydroxy-4-nitro-benzylidene)-thiazolidine-2,4-dione;  
5-(4-Amino-3-hydroxy-benzylidene)-thiazolidine-2,4-dione;  
(E)-3-(4-amino-3-hydroxy-phenyl)-2-methyl-acrylic acid ethyl ester hydrochloride;  
2-(3-ethylcyclopentyl)-5-methyl-2,4-dihydroxyprazol-3-one;  
2-[3-(1,1-dimethylpropyl)-cyclopentyl]-5-methyl-2,4-dihydroxyprazol-3-one;  
(E)-3-(3-Hydroxy-4-nitrophenyl)-2-methylacrylic acid ethyl ester;  
(E)-3-(4-Amino-3-hydroxy-phenyl)-2-methyl-acrylic acid ethyl ester hydrochloride;

3-Ethylcyclopentylhydrazine trifluoroacetate; and

3-(1,1-Dimethylpropyl)-cyclopentylhydrazine trifluoroacetate.

51. (ORIGINAL) A compound of claim 1 selected from:

3'-(1-Cyclohexyl-5-hydroxy-3-methyl-1H-pyrazol-4-ylazo)-2'-hydroxy-biphenyl-3-carboxylic acid;

5-{4-[1-(4-tert-Butyl-cyclohexyl)-5-hydroxy-3-methyl-1H-pyrazol-4-ylazo]-3-hydroxy-benzylidene}-thiazolidine-2,4-dione;

(E)-3-{4-[1-(4-tert-butylcyclohexyl)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-4-ylazo]-3-hydroxyphenyl}-2-methylacrylic acid;

(E)-3-(4-{N'-3-Ethylcyclopentyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]-hydrazino}-3-hydroxyphenyl)-2-methylacrylic acid; and

(E)-3-[4-(N'-{1-[3-(1,1-Dimethylpropyl)-cyclopentyl]-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene}-hydrazino)-3-hydroxyphenyl]-2-methylacrylic acid;

and pharmaceutically acceptable salts, hydrates, solvates and esters thereof.